Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 16/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 1/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433279 | 0.90 | CPB2 (0.50) | CPB2FNTAFNTBPGGT1BMMP3 | |
| SCHEMBL31433188 | 0.89 | CPB2 (0.51) | CPB2FNTAFNTBPGGT1BMMP3 | |
| SCHEMBL31433190 | 0.85 | MMP3 (0.47) | CPB2FNTAFNTBPGGT1BMMP1 | |
| SCHEMBL31433246 | 0.84 | CPB2 (0.74) | CPB2 | |
| SCHEMBL29476600 | 0.82 | CPB2 (0.52) | CPB2FNTAFNTBPGGT1B | |
| SCHEMBL7751628 | 0.81 | CPB2 (0.51) | CPB2FNTAFNTBPGGT1BMME | |
| SCHEMBL29641088 | 0.80 | CPB2 (0.49) | CPB2FNTAFNTBPGGT1BCTSL | |
| SCHEMBL7361350 | 0.78 | METAP2 (0.61) | CPB2 | |
| SCHEMBL7355867 | 0.78 | METAP2 (0.61) | CPB2 | |
| SCHEMBL31688084 | 0.78 | CPB2 (0.50) | CPB2FNTAFNTBPGGT1BMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CPB2 948/4885FNTA 3629/4885FNTB 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.